Robert Scott, MD, has joined the Board of Directors of OncoSpherix.
Dr. Scott has held leadership positions in global Pharma for over thirty years. At Pfizer, he developed Lipitor and Norvasc. He also invented and developed the first commercially available Polypill, Caduet. At AtheroGenics, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. At Amgen, he conducted the first outcome study for a PCSK9i, FOURIER. Dr. Scott was able to accelerate the program by 18 months and achieve the first regulatory approval in a highly competitive race. He recently retired as the Chief Medical Officer at Abbvie where he had responsibility for around 40 new molecular entities, four thousand people and a budget of close to two billion dollars. During his tenure, Abbvie achieved over 14 major regulatory approvals including Venclexta, Orilissa, Skyrizi and Rinvoq. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics and big data to design and implement better clinical trials. He has been a board member of Transcelerate and the PhRMA R&D Leadership Forum. Dr. Scott is a leader in digital transformation of clinical research including a broad range of aspects from predictive analytics, innovative program and study design, synthetic and historical controls, pragmatic and real world studies, use of passive data collection using IoT and wearables and risk based monitoring to name a few. . “We are honored to have Dr. Scott join our Board of Directors” stated Dr. Margaret K. Offermann, CEO of OncoSpherix. “He is an innovative thinker whose accomplishments speak for themselves. His knowledge and perspective will be invaluable as we advance our HIF inhibitors to clinical testing and beyond. He shares our commitment to do what is best for patients as we strive for better outcomes for patients with advanced cancer”.